We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
+$45.6M
Cap. Flow
+$18.2M
Cap. Flow %
6.78%
Top 10 Hldgs %
33.7%
Holding
508
New
146
Increased
78
Reduced
73
Closed
186

Top Buys

1
TSEM icon
Tower Semiconductor
TSEM
+$9.09M
2
LITE icon
Lumentum
LITE
+$8.24M
3
GLW icon
Corning
GLW
+$6.49M
4
INTC icon
Intel
INTC
+$5.94M
5
ALAB icon
Astera Labs
ALAB
+$4.77M

Top Sells

1
CNC icon
Centene
CNC
+$9.07M
2
MOH icon
Molina Healthcare
MOH
+$8.9M
3
ELV icon
Elevance Health
ELV
+$8.08M
4
BTSG icon
BrightSpring Health Services
BTSG
+$3.52M
5
TERN
Terns Pharmaceuticals
TERN
+$2.78M

Sector Composition

1 Technology 44.62%
2 Healthcare 29.67%
3 Financials 9.04%
4 Consumer Discretionary 3.92%
5 Energy 3.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
201
Ultragenyx Pharmaceutical
RARE
$2.98B
$186K 0.07%
8,884
-2,145
-19% -$48.3K
ARGX icon
202
argenx
ARGX
$53.7B
$185K 0.07%
253
-311
-55% -$243K
STRO icon
203
Sutro Biopharma
STRO
$393M
$185K 0.07%
+7,411
New +$134K
KALV
204
DELISTED
KalVista Pharmaceuticals
KALV
$181K 0.07%
+9,001
New +$145K
ALMS
205
CALL
Alumis Inc
ALMS
$3.47B
$179K 0.07%
+253
New +$6.33K
UNCY icon
206
Unicycive Therapeutics
UNCY
$138M
$177K 0.07%
+26,827
New +$176K
FBRX icon
207
Forte Biosciences
FBRX
$921M
$175K 0.07%
6,744
-3,402
-34% -$98K
TYRA icon
208
Tyra Biosciences
TYRA
$1.88B
$173K 0.06%
+4,518
New +$146K
DRUG
209
Bright Minds Biosciences
DRUG
$728M
$169K 0.06%
+2,310
New +$186K
ARWR icon
210
Arrowhead Research
ARWR
$10.1B
$167K 0.06%
+2,661
New +$168K
SPRB
211
Spruce Biosciences
SPRB
$122M
$165K 0.06%
+2,528
New +$174K
CERT icon
212
Certara
CERT
$1.13B
$163K 0.06%
28,623
+15,832
+124% +$121K
RLAY icon
213
Relay Therapeutics
RLAY
$4.22B
$163K 0.06%
+16,358
New +$146K
GEHC icon
214
GE HealthCare
GEHC
$29.9B
$159K 0.06%
2,237
+325
+17% +$25.6K
EYPT icon
215
CALL
EyePoint Inc
EYPT
$1.09B
$154K 0.06%
+269
New +$4.02K
LQDA icon
216
CALL
Liquidia Corp
LQDA
$6.69B
$154K 0.06%
+1,675
New +$62.1K
DHT icon
217
DHT Holdings
DHT
$2.87B
$153K 0.06%
+8,386
New +$134K
CRMD icon
218
PUT
CorMedix
CRMD
$650M
$150K 0.06%
427
– –
UTHR icon
219
CALL
United Therapeutics
UTHR
$22.5B
$141K 0.05%
+102
New +$50.8K
DMRA
220
Damora Therapeutics
DMRA
$1.86B
$138K 0.05%
+5,338
New +$137K
ADAG
221
Adagene
ADAG
$237M
$138K 0.05%
+35,126
New +$102K
SLSR
222
Solaris Resources
SLSR
$1.21B
$138K 0.05%
15,956
-10,160
-39% -$93.7K
NVO
223
Novo Nordisk
NVO
$228B
$135K 0.05%
+3,685
New +$175K
PSNL icon
224
Personalis
PSNL
$1.63B
$133K 0.05%
+20,929
New +$177K
CNTB
225
Connect Biopharma Holdings
CNTB
$147M
$133K 0.05%
50,747
+23,973
+90% +$62.5K
7 8
9
10 11

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Persistent Asset Partners held 508 positions worth $268M, up 20% from $223M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Persistent Asset Partners deployed $18.2M of net new capital in Q1 2026, opening 146 new positions and adding to 78 existing holdings. Its largest new stake was Tower Semiconductor: 67,608 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.78M trimmed.

  • Persistent Asset Partners's largest Q1 2026 buy was Tower Semiconductor: 67,608 shares worth $11.9M.
  • Persistent Asset Partners added most to Lumentum in Q1 2026, an estimated $8.24M increase.
  • Persistent Asset Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $2.78M.
  • Persistent Asset Partners fully exited Centene in Q1 2026, selling an estimated $9.07M.
  • Persistent Asset Partners's ten largest holdings make up 34% of its $268M portfolio in Q1 2026.
  • Persistent Asset Partners opened 146 new positions and closed 186 in Q1 2026.
  • Persistent Asset Partners's portfolio value rose 20% quarter-over-quarter to $268M.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.